ArticleBiochemistry and biophysics reports2026
Structural and morphological modulation of the myocardium by
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study investigated the ameliorative potential of a saponin derived from Methods: Forty-eight rats were divided into eight groups (n = 6). Group A received distilled water, and Group B received doxorubicin (10 mg/kg). Groups C and D received SRF (50 or 100 mg/kg) for 14 days. Groups E and F received doxorubicin with SRF, while Groups G and H were pretreated with SRF before doxorubicin on day 15. Blood and heart tissues were collected for analysis after euthanasia. Results: Rats in the doxorubicin-only group (Group B) exhibited significant elevations in serum cardiac injury markers, including lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB), along with increased systolic and diastolic blood pressures and elevated malondialdehyde (MDA) levels. Conversely, activities of key antioxidant enzymes-superoxide dismutase (SOD) and catalase (CAT)-were markedly reduced. Enhanced glycogen accumulation, Caspase-3 activation, and CD4 expression further indicated heightened oxidative stress and apoptosis. Treatment with SRF, particularly in the pre- and co-administration protocols, significantly attenuated these alterations. Conclusion: The saponin-rich fraction of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.